Skip to content

At IRBM, we have all the tools necessary to fully characterize your antibody leads. Our assays range from measuring binding kinetic parameters using SPR or BLI, to epitope binning, to cell and tissue specificity measures and in vivo studies of efficacy.

With our deep expertise in identifying and profiling antibodies our team will ensure your therapeutic leads are highly specific and fit-for-purpose.

We’ll fully characterize your antibody in terms of biochemical, functional and pharmacokinetic properties, assess its specificity pattern on tissue by histology, and testing efficacy in vivo in the most aappropriate mouse model.

IRBM’s model systems to test antibodies with therapeutic potential, include cell-derived xenografts, syngeneic mice, humanized mouse models and engineered cell lines expressing bioluminescent reporter genes.

OUR STATE-OF-THE-ART ASSAYS INCLUDE:

  • Binding kinetics parameters by SPR or BLI
  • Epitope binning
  • Binding and affinity on target cells: Cell-Based ELISA, FACS analysis
  • Cell-based functional assays: internalization by IF, ADC, ADCC, CDC, cell toxicity, receptor agonism/antagonism
  • Tissue specificity by IHC
  • In vivo studies: MTD, efficacy in Xenograft models, IHC
DISCOVER MORE ABOUT OUR ANTIBODY CHARACTERIZATION ASSAYS

PK, PD,
BIOANALYTICS

BIOPHISICAL
APPROACHES

Back To Top